The Eger Macular treometer: pilot tudy

Purpoe To evaluate the enitivity of the Eger Macular treometer (EM) for early creening of age-related macular degeneration (AMD) in a clinical practice. We examined the null hypothei that AMD eye have EM recovery time (RT) that do not differ from eye with cataract, diabetic retinopathy, or glaucoma. Deign The deign of thi tudy wa a nonrandomized clinical trial. Method Ninety-two eye from 92 patient with viion 20/80 or better, age 50 and older, of either gender, and any ethnic origin, were recruited into one of four group: AMD (30 eye), normal or mild cataract (30 eye), diabetic retinopathy (16 eye), and glaucoma (16 eye). Recovery time were obtained with the EM, according to manufacturer’ intruction. Reult The mean (D) [median] RT for the AMD group wa 11.8 (7.6) [9] econd, the normal/cataract group 10.0 (4.3) [9] econd, the diabetic retinopathy group 8.4 (3.0) [8] econd, and glaucoma group 8.6 (2.4) [8] econd. Recovery time did not appear to be related to group (P = .58), age (P = .50), viual acuity (P = .52), or ex (P = .23). Concluion We found EM RT ditribution did not differ between AMD, cataract, diabetic retinopathy, and glaucoma group. The EM in it current form i not a enitive creening tool for AMD. Further teting i needed to examine EM enitivity with other macular dieae uch a central erou choroidopathy and diabetic macular edema.